Mission Statement
Corthera is a biopharmaceutical company committed to acquiring, developing and commercializing therapeutics in the acute care setting.
Relaxin
Corthera’s lead product candidate, relaxin, is a naturally occurring peptide hormone that acts as a systemic and targeted renal vasodilator.
Relaxin is currently being evaluated in a global, phase 2/3 clinical trial for acute decompensated heart failure.
In The News
January 08, 2008
Corthera Initiates Phase II Clinical Trail of Relaxin in Acute Heart Failure
December 20, 2007
Corthera Closes $23 Million Financing Round